CD274 and non-small cell lung carcinoma: Immune checkpoint therapy (immunotherapy) targeting the programmed cell death protein 1/programmed death‐ligand 1 (PD‐L1) pathway3 has greatly improved survival for NSCLC patients.4, 5, 6